A. Iannitelli, P. Pancheri - Vol. 8, December 2002, Issue 4
Testo Immagini Bibliografia Summary Indice
Citalopram: profilo farmacologico e indicazioni
cliniche del più selettivo tra gli SSRI
CItalopram: pharmacological profile and clinical efficacy of the most selective
among SSRI
1 Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes
as possible determinant of the thymoleptic effect. Lancet 1969;1:132-6.
2 Curzon G. Transmitter amines in depression. Psychological Med 1982;12:465-70.
3 Asberg M, Eriksson B, Martensson B Traskman-Bendz L, Wagner A. Therapeutic effects of serotonin uptake inhibitors in depression. J Clin Psychiatry 1986;47(Suppl. 4):23-35.
4 Kasper S, Fuger J, Moller HI. Comparative efficacy of antidepressants. Drugs 1992;43(Suppl.2):11-23.
5 Kasper S, Hoflich G, Scholl HP, Müller HJ. Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors. Hum Psychopharmacol 1994;9:1-12.
6 Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306:683-7.
7 Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants J Psychopharmacol (Oxf) 1994;8:238-49.
8 Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 1998;59(Suppl. 15):19-27.
9 Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Human cytochromes and some newer antidepressants: kinetics, metabolism and drug interactions. J Clin Psychopharmacol 1999;19:23S-35S.
10 Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998;59(Suppl. 15):42-8.
11 Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a metaanalysis and investigation of heterogeneity. Br J Psychiatry 1997;170:12-127.
12 Martensson B, Aberg-Wiestedt A. The use of selective serotonin reuptake inhibitors among Swedish psychiatrists. Nordic J Psychiatry 1996;50:443-50.
13 Keller MB. Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. J Clin Psychiatry 2000;61:896-908.
14 Bollettino di Informazione sui Farmaci VIII 1, 2001.
15 Holden C. Global survey examines impact of depression. Science 2000;288:39-40.
16 Dupont RL. Panic disorder and addiction: the clinical issues of co-morbidity. Bull Menninger Clin 1997;61:A54-65.
17 Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry 1990;147:1049-51.
18 Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001;11:275-83.
19 Hyttel J. Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171. Psychopharmacology 1977;51:225-33.
20 Pedersen OL, Bjerre M, Kragh-Sorensen P, Kristensen CB, Overø KF. Clinical evaluation of citalopram (Lu10-171)-a specific %-HT uptake inhibitor. Abstracts of the 12th CINP Congress. Goteborg, 22-26 June 1980. In: Radonco-Thomas C, Garcin F (eds.). Oxford: Pergamon Press, p. 229, abstract 408.
21 Pawlowski L, Ruczynska J, Gorka Z. Citalopram: a new potent inhibitor of serotonin (5-HT) uptake with central 5-HT-mimetic properties. Psychopharmacology 1981;74:161-5.
22 Gottlieb P, Wandall T, Overo FK. Initial, clinical trial of a new specific 5-HT reuptake inhibitor, citalopram (Lu10-171). Acta Psychiatr Scand 1980;62;236-44.
23 Pedersen OL, Kragh-Sorensen P, Bjerre M, Overø FK, Gram LF. Citalopram, a selective serotonin reuptake inhibitor: clinical antidepressive and long term effect. A phase II study. Psychopharmacology 1982;77:199-204.
24 Ofsti E. Citalopram – a specific 5-HT-reuptake inhibitor as an antidepressant drug: a phase II multicentre trial. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:327-35.
25 Joubert AF, Sanchez C, Larsen F. Citalopram. Hum Psychopharmacol 2000;15:439-51.
26 Hyttel J. Citalopram – pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:277-95.
27 Hyttel J, Arnt J, Sanchez C. The pharmacology of citalopram. Rev Contemporary Psychopharmacother 1995;6:271-85.
28 Christensen AV, Fjalland B, Pedersen V, Danneskiold-Samsoe P, Svendsen O. Pharmacology of a new phthalane (Lu 10-171), with specific 5-HAT uptake inhibiting properties. Eur J Pharmacol 1977;41:153-62.
29 Hyttel J, Larsen JJ. Serotonin-selective antidepressants. Acta Pharmacol Toxicol 1985;56(Suppl. 1):146-53.
30 Keshavan HJ, Gurbani NK, Dandiya PC. Effect of citalopram (Lu 10-171) on tranylcypromine and triptophan-induced wet-dog shakes in rats. Psychopharmacology 1980;70:209-12.
31 Da Prada M, Bonetti EP, Scherschlicht R, Bondiolotti GP. Serotonin involvement in lisuride-induced mounting and in sleep. Pharmacopsychiatry 1985;18:202-8.
32 Sanchez C, Hyttel J. Comparison of the effect of antidepressant and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999;19:467-89.
33 Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992;88:157-60.
34 Pollock BG. Citalopram: a comprehensive review. Expert Opin Pharmacother 2001;2:681-98.
35 Noble S, Benfield P. Citalopram. A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 1997;8:410-31.
36 Sanchez C, Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology 1997;129:197-205.
37 Hyttel J, Overø FK, Arnt J. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology 1984;83:20-7.
38 Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995;6:287-95.
39 Overø FK, Toft B, Christophersen L, Gylding-Sabroe P. Kinetics of citalopram in elderly patients. Psychopharmacology 1985;86:253-7.
40 Rochat B, Amey M, Gillet M, Meyer UA, Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Transient expression of the serotonin transporter in the developing mouse thalamocortical system. Pharmacogenetics 1997;7:1-10.
41 Von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Duan SX, et al. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects. Biol Psychiatry 1999;46:839-49.
42 Jeppesen U, Gram L, Vistisen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
43 Overø FK. Kinetics of citalopram in man: plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:311-8.
44 Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(Suppl. 1):19-26.
45 Przegalinski E, Moryl E, Papp M. The effect of 5-HT1A receptor ligands in chronic mild stress model of depression. Neuropharmacology 1995;34:1305-10.
46 Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 1992;16:525-34.
47 Sanchez A, Niedbela B, Lferia M. Modulation of neuropathic pain in rats by intrathecally injected serotonergic agonists. Neuroreport 1995;6:2585-8.
48 Sanchez C, Hyttel J. Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT1A receptors. Eur J Pharmacol 1994;264:241-7.
49 Hochstrasser B, Isaksen PM, Koponen H, Lauritzen L, Mahnert FA, Rouillon F, et al. Prophylactic effect of citalopram in unipolar, recurrent depression. Placebo controlled study of maintenance therapy. Br J Psychiatry 2001;178:304-10.
50 Mendels J, Kiev A, Fabre LF. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety 1999;9:54-60.
51 Montgomery SA, Pedersen V, Tanghøj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram – a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 1994;9(Suppl. 1):35-40.
52 Bech P, Cialdella P. Citalopram in depression: Meta-analysis of intended and unintended effects. Biol Psychiatry 1991, Vol. I (G. Racagni et al., eds).
53 de Wilde J, Mertens C, Overø FK, Petersen HE. Citalopram versus mianserin. A controlled, double-blind trial in depressed patients. Acta Psychiatr Scand 1985;72:89-96.
54 Ahlfors UG, Elovaara S, Harma P, Suoniemi I, Heikkilä L, Nummi K, et al. Clinical multicentre study of citalopram compared double-blindly with mianserin in depressed patients in Finland. Nord Psykiatr Tidsskr 1988;42:201-10.
55 Bouchard JM, Delaunay J, Delisle JP, Grasset N, Mermberg PF, Molczadzki M, et al. Citalopram versus Maprotiline: A controlled, clinical multicentre trial in depressed patients. Acta Psychiatr Scand 1987;76:583-92.
56 Shaw DM, Crimmins R. A multicentre trial of citalopram and amitriptyline in major depressive illness. XXII Nord Psykiater-Kongres, Excerpta Medica 1989:43-9.
57 Patris M, Bouchard JM, Bougerol T, Charbonnier J-F, Chevalier J-F, Clerc G. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996;11:129-36.
58 Bougerol T, Scotto JC, Patris M, Strub N, Lemming O, Høpfner Petersen HE. Citalopram and fluoxetine in major depression. Comparison of two clinical trials in a psychiatrist setting and in general practice. Clin Drug Invest 1997;14;77-89.
59 Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000;48:894-901.
60 Bouchard JM, Strub N, Nil R. Citalopram and viloxazine in the treatment of depression by means of slow drop infusion. A double-blind comparative trial. J Affect Disord 1997;46:51-8.
61 Baumann P, Nil R, Bertschy G, Jecker A, Brändli H, Morand J, et al. A double-blind double-dummy study of citalopram comparing infusion versus oral administration. J Affect Disord 1998;49:203-10.
62 Guelfi JD, Strub N, Loft H. Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial. J Affect Disord 2000;58:201-9.
63 Montgomery SA, Rasmussen JGC, Tanghøj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-8.
64 Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;10(Suppl. 1):29-35.
65 Montgomery S. Effectiveness of 20 mg/day Citalopram in the Prevention of Depression Relapse. Annual Meeting of American Psychiatric Association, May 15-20; 1999.
66 Franchini L, Spagnolo C, Rampoldi R, Zanardi R, Smeraldi E. Long–term treatment with citalopram in patients with higly recurrent forms of unipolar depression. Psychiatry Res 2001;105:129-33.
67 Wade AG. Prevention of depression recurrence with citalopram: results from a double-blind, placebo-controlled trial. In: New Research Program and Abstracts of the 152nd Annual Meeting of the American Psychiatric Association: May 20, 1999, Washington DC Abstract NR643:250.
68 Dunner DL, Hendricksen HE, Bea C, Budech CB, Friedman SD. Dysthimic disorder: treatment with citalopram. Depress Anxiety 2002;15:18-22.
69 Kupfer DJ, Chengappa KNR, Gelenberg AJ, Hirschfeld RMA, Goldberg JF, Sachs GS, et al. Citalopram as adjunctive therapy in bipolar depression. J Clin Psychiatry 2001;62:985-90.
70 Jefferson JW, Greist JH. Citalopram compared to paroxetine in depressed patients with associated anxiety. APA, New Orleans, May 2001.
71 Jefferson JW, Greist JH. A double-blind comparison of citalopram and paroxetine in the treatment of patients with depression and anxiety. Annual Meeting American College of Neuropsychopharmacology December 10-14, 2000.
72 Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatry 1997;170:549-53.
73 Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjödin I, et al. A Controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998;59:528-34.
74 Leinonen E, Lepola U, Koponen H, Turtonen J, Wade AG, Lehto H. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosc 2000;25:24-32.
75 Wade AG. Antidepressant in panic disorder. Int Clin Psychopharmacol 1999;14(Suppl. 2):S13-7.
76 Perna G, Bertani A, Caldirola D, Smeraldi E, Bellodi L. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2001;34:85-90.
77 Seedat S, Stein DJ, Emsley RA. Open trial of citalopram in adults with post-traumatic stress disorder. Int J Neuropsychopharmacol 2000;3:135-40.
78 Marazziti D, Dell’Osso L, Gemignani A, Ciapparelli A, Presta S, Di Nasso E, et al. Citalopram in refractory obsessive-compulsive disorder: an open study. Int Clin Psychopharmacol 2001;16:215-9.
79 Montgomery SA, Kasper S, Stein DJ, Hedegaard KB, Lemming OM. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16:75-86.
80 Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25:1099-104.
81 Andersen G. Treatment of uncontrolled crying after stroke. Drugs & Aging 1995;6:105-11.
82 Pallanti S, Quercioli L, Ramacciotti A. Citalopram in anorexia nervosa. EWD, 1997
83 Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998;18:390-8.
84 Angelone SM, Bellini L, Di Bella D, Catalano M. Effects of fluvoxamine and citalopram in maintaining abstinence in a sample of italian detoxified alcoholics. Alcohol & Alcohol 1998;2:151-6.
85 Hovorka J, Herman E, Nemcová I. Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy & Behavior 2000;1:444-7.
86 Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia – a randomized, double-blind, placebo-controlled study. Europ J Pain 2000;4:27-35.
87 Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry 2002;63:44-8.
88 Rasmussen SL, Overø KF, Tanghøj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999;19:407-15.
89 Gottfries CG. Scandinavian experience with citalopram in the elderly. Int Clin Psychopharmacol 1996;11(Suppl. 1):41-4.
90 Kyle CJ, Høpfner Petersen HE, Overø FK. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depression and Anxiety 1998;8:147-53.
91 Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138-45.
92 Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990;157:894-901.
93 Gottfries CG. Citalopram: its use in elderly patients. Ann Long-Term Care 1999;7:181-9.
94 Klysner R, Bent-Hansen J, Hansen HL, Lunde M, Pleidrup E, Loldrup Poulsen DL, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002;181:29-35.
95 Pollock BG, Benoit HM, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002;159:460-65.
96 Muldoon C. The safety and tolerability of citalopram. Int Clin Psychopharmacol 1996;11(Suppl. 1):35-40.
97 Waldinger MD, Zwinderman A, Olivier B. SSRIs and ejaculation: a double-blind, randomized, comparative fixed-dose study with paroxetine and citalopram. In: New Research Abstracts of the 153rd Annual Meeting of the American Psychiatric Association, May 18, 2000, Chicago III, Abstract NR685:242.
98 Markowitz JS, Devane CL. Effects of abrupt discontinuation of citalopram. In: New Research Program and Abstracts of the 152nd Annual Meeting of the American Psychiatric Association; May 20, 1999, Washington DC, Abstract NR685-262.
99 Michelson D, Tamura R, Tepner R, et al. Physiological correlates of SSRI withdrawal: evidence from a controlled, randomized trial of fluoxetine, sertraline and paroxetine. Presented at the 37th annual meeting of the American College of Neuropsychopharmacology; Dec 14-18, 1998, Las Croabas, Puerto Rico.
100 Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996;42:757-63.
101 Haffmans PMJ, Timmerman L, Hoogduin CAL and LUCIFER group. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. Int Clin Psychopharmacol 1996;11:157-64.
102 Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997;12:323-31.
103 Kyle CJ, Petersen HE, Overø KF. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998;8:147-53.
104 Brøsen K. Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Psychopharmacol 1996;11(Suppl. 1):23-7.
105 Gram LF, Hansen MGJ, Sindrup SH, Brøsen K, Poulsen JH, Aaes-Jørgensen T, Overø FK. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993;15:18-24.
106 Lader M, Melhuish A, Freka G, Fredericson Overø K, Christensen V. The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol 1986;31:183-90.